Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Study to Evaluate the Pharmacokinetics (PK) of E7090 and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of E7090 after a single dose administration.

hepatic impairment
moderate hepatic impairment
e7090
body mass index
electrocardiogram (ecg)
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

hepatic impairment
moderate hepatic impairment
body mass index
liver disease
moderate hepatic insufficiency
  • 0 views
  • 16 Feb, 2024
  • 1 location
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

systolic blood pressure
aprocitentan
follicle stimulating hormone
bilateral salpingectomy
diastolic blood pressure
  • 0 views
  • 16 Feb, 2024
  • 1 location